110 completed, 68 recruiting, 59 terminated, 41 active not recruiting. 167 Phase 2, 119 Phase 1, 40 Phase 3, 13 Not applicable, 5 Early Phase 1.
Follow Follicular Lymphoma: new trials by email Literature Review of Follicular Lymphoma trials Research Report on Follicular Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid Neoplasms: First-in-human Administration, COLIBRI. CAR-T anti-CD19 COL01 - Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, Lymphoid Malignancies | Phase 1 | Not yet recruiting | GUSTAVO SALGUERO | 12 | 2027-04-01 | 2026-10-20 |
| Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphoma Epcoritamab, Observation - Randomized, Phase 2 | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 40 | 2027-02-12 | 2026-11-02 |
| A Study Comparing a New Drug (Surovatamig) With Standard Radiotherapy With or Without Rituximab in Adults With Limited Stage Nodal Follicular Lymphoma Surovatamig, Involved Site Radiotherapy (ISRT), Involved-Site Radiotherapy (ISRT) + Rituximab - Follicular Lymphoma | Phase 3 | Not yet recruiting | Australasian Leukaemia and Lymphoma Group | 140 | 2027-01-12 | 2026-09-30 |
| Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) Allogeneic NK cells, Rituximab, Tafasitamab - Non Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma | Phase 1 | Recruiting | Paolo Caimi, MD | 15 | 2026-09-01 | 2026-09-09 |
| Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL) Non-Hodgkin Lymphoma, T-Cell Lymphoma | Recruiting | Natera, Inc. | 200 | 2026-07-27 | 2026-08-06 | |
| A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007) MK-1045, Rituximab, Rituximab biosimilar - Follicular Lymphoma | Phase 2 / Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 960 | 2026-06-22 | 2026-11-13 |
| Evaluation of Skin Tests in Biotherapy Allergies Drug skin tests (investigating hypersensitivity to a biotherapy) - Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Melanoma Neoplasms | Not applicable | Recruiting | University Hospital, Angers | 70 | 2026-06-17 | 2026-06-18 |
| Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies Follicular Lymphoma | Withdrawn | Ipsen | 2026-06-01 | 2026-04-29 | ||
| Pomalidomide Plus Anti-CD20 Antibody and Prednisone in Frontline Indolent B-Cell Lymphoma Pomalidomide - Indolent Lymphoma, Follicular Lymphoma | Not yet recruiting | The First Affiliated Hospital of Soochow University | 30 | 2026-05-01 | 2026-05-27 | |
| A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers LY4584180, Rituximab - Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell | Phase 1 | Recruiting | Eli Lilly and Company | 460 | 2026-04-17 | 2026-11-04 |
| A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide Orelabrutinib, Tafasitamab, Lenalidomide - Follicular Lymphoma | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 27 | 2026-04-15 | 2026-05-14 |
| Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma Mosunetuzumab, Zeprumetostat - Follicular Lymphoma | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 80 | 2026-04-10 | 2026-06-09 |
| Trial to Evaluate Efficacy and Safety of Subcutaneous Mosunetuzumab in Previously Untreated Low Tumor Burden Follicular Lymphoma . Mosunetuzumab is a bispecific monoclonal antibody targeting CD20 on B cells and CD3 on T cells, redirecting T cells to eliminate malignant B cells. - Follicular Lymphoma | Phase 2 | Recruiting | Tel-Aviv Sourasky Medical Center | 40 | 2026-01-05 | 2026-08-11 |
| Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular Lymphoma Induction Therapy: Zanubrutinib, obinutuzumab, lenalidomide, Maintenance therapy: Zanubrutinib, lenalidomide - Follicular Lymphoma | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 34 | 2025-12-25 | 2026-05-13 |
| Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma TQB2825 Injection, Rituximab Injection - Follicular Lymphoma | Phase 3 | Not yet recruiting | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | 228 | 2025-11-01 | 2025-09-23 |
| Odronextamab in Low Tumor Volume Advanced FL Odronextamab - Follicular Lymphoma, Lymphoma | Phase 2 | Recruiting | Gottfried von Keudell, MD PhD | 35 | 2025-09-08 | 2026-03-13 |
| A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation Tazverik (Tazemetostat) - Follicular Lymphoma, Refractory Follicular Lymphoma | Phase 2 | Withdrawn | Epizyme, Inc. | 2025-09-02 | 2026-01-30 | |
| HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL Tafasitamab, Rituximab, Lenalidomide - Follicular Lymphoma, Marginal Zone Lymphoma | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 65 | 2025-08-07 | 2026-08-12 |
| A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4) Golcadomide, Rituximab, Lenalidomide - Follicular Lymphoma | Phase 3 | Recruiting | Celgene | 400 | 2025-07-28 | 2026-05-20 |
| Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma zanubrutinib, bendamustine, and obinutuzumab - Follicular Lymphoma, Treatment Naive | Not applicable | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 15 | 2025-07-15 | 2025-08-17 |
Showing 20 of 345. Sign in to see all of them.
Lymphoma, Follicular (345) · Lymphoma, Mantle-Cell (108) · Lymphoma, Large B-Cell, Diffuse (106) · Lymphoma, B-Cell, Marginal Zone (99) · Leukemia, Lymphocytic, Chronic, B-Cell (88) · Lymphoma, Non-Hodgkin (88) · Lymphoma (61) · Lymphoma, B-Cell (42) · Burkitt Lymphoma (30) · Waldenstrom Macroglobulinemia (25) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (23) · Multiple Myeloma (21) · Recurrence (18) · Leukemia, Myeloid, Acute (16) · Neoplasms (14)
Hemic and Lymphatic Diseases (345) · Immune System Diseases (344) · Neoplasms by Histologic Type (344) · Immunoproliferative Disorders (343) · Lymphatic Diseases (342) · Lymphoproliferative Disorders (342) · Neoplasms (331) · Lymphoma (284) · Lymphoma, Non-Hodgkin (257) · Lymphoma, B-Cell (134) · Pathologic Processes (110) · Pathological Conditions, Signs and Symptoms (110) · Hematologic Diseases (108) · Disease Attributes (106) · Leukemia, Lymphoid (94)
Rituximab (87) · Cyclophosphamide (43) · Lenalidomide (26) · Bendamustine Hydrochloride (25) · fludarabine (25) · obinutuzumab (24) · Prednisone (17) · Vincristine (17) · Doxorubicin (13) · fludarabine phosphate (13) · Whole-Body Irradiation (10) · venetoclax (10) · Bortezomib (9) · ibrutinib (9) · tazemetostat (9)
Fondazione Italiana Linfomi - ETS (10) · Masonic Cancer Center, University of Minnesota (9) · Gilead Sciences (8) · Hoffmann-La Roche (8) · The Lymphoma Academic Research Organisation (8) · National Cancer Institute (NCI) (7) · M.D. Anderson Cancer Center (6) · Memorial Sloan Kettering Cancer Center (6) · Lymphoma Study Association (5) · Massachusetts General Hospital (5) · Medical College of Wisconsin (5) · PersonGen BioTherapeutics (Suzhou) Co., Ltd. (5) · Ruijin Hospital (5) · Weill Medical College of Cornell University (5) · Epizyme, Inc. (4)
United States (193) · France (51) · China (49) · Italy (47) · Australia (36) · Spain (36) · United Kingdom (25) · Canada (24) · Germany (24) · Belgium (20) · South Korea (19) · Poland (18) · Japan (16) · Israel (15) · Netherlands (12)
Reid Merryman, MD (3) · Ajay K. Gopal (2) · Bertrand Coiffier, MD (2) · Bing Xu (2) · Claudio Brunstein, MD, PhD (2) · Eliza Hawkes, MD (2) · Franck Morschhauser, MD, PhD (2)
PMID 34515338, PMID 34398557, PMID 26248505, PMID 30184451, PMID 32888407, PMID 35947804, PMID 39374535, PMID 41915772, PMID 10586336, PMID 17242396, PMID 18239086, PMID 18344536, PMID 18955565, PMID 21073974, PMID 21176949, PMID 22535574, PMID 22885164, PMID 23233718, PMID 23812930, PMID 23834234, PMID 24297953, PMID 24450858, PMID 24831981, PMID 25016003, PMID 25029908, PMID 25145344, PMID 25293773, PMID 25439689, PMID 25502635, PMID 25596266, PMID 25696919, PMID 26205583, PMID 26482097, PMID 26659089, PMID 26659572, PMID 26738796, PMID 26913560, PMID 27354476, PMID 27879257, PMID 28054442, PMID 28291388, PMID 28490569, PMID 28701367, PMID 28712941, PMID 28774879, PMID 28945884, PMID 29095677, PMID 29226797, PMID 29437592, PMID 29709062
2023 (6), 2017 (5), 2014 (3), 2016 (3), 2019 (3), 2015 (2), 2018 (2), 2025 (2), P30CA033572 (2), U24CA076518 (2), 2008 (1), 2009 (1), P30CA015704 (1), P30CA016672 (1), R01CA193140 (1)